Description
Bifidobacterium longum is one of the dominant native species in the adult human colon and a foundational ingredient in clinically-positioned probiotic formulations targeting immune, gut, and stress-response health.
Supplied as a freeze-dried powder with viability between 100 and 500 billion CFU per gram at release. The species is more oxygen-sensitive than B. lactis, requiring more careful downstream handling but offering more authentic representation of the native adult colonic flora.
Off-white to pale beige free-flowing powder with a neutral fermented note. Particle size suitable for capsule, sachet, and dairy applications.
We supply food-grade Bifidobacterium longum from manufacturers in China holding ISO 22000, FSSC 22000, Halal, Kosher, and other certifications relevant to probiotic strain production.
Common market grades include 100, 200, and 500 billion CFU per gram freeze-dried powders, microencapsulated grades for oxygen and acid protection, and B. longum subsp. infantis derivatives for pediatric and infant formula applications. Bulk and reduced-MOQ shipments with batch-level COA covering viable count, strain identity, moisture, heavy metals, and pathogen panel.
Introduction
Bifidobacterium longum was first isolated from infant feces by Henry Tissier in 1899 and has been studied continuously since. The reference commercial strain BB536 was isolated in Japan by Morinaga Milk Industry in 1969 and is deposited at ATCC under accession BAA-999. It is one of the most clinically-documented Bifidobacterium strains globally.
Industrial production proceeds by anaerobic fermentation in semi-defined media supplemented with reducing agents and growth factors specific to Bifidobacterium metabolism. Biomass is recovered under controlled atmosphere, cryoprotected with trehalose or sucrose, and lyophilized to residual moisture below 4 percent. Oxygen exposure during processing is minimized through nitrogen-blanketed equipment.
Regulatory status includes GRAS notification with FDA, Qualified Presumption of Safety listing in the European Union, and use in approved infant formula products in major regulatory regions.
Clinical evidence supports use for relief of seasonal allergic symptoms, reduction of upper respiratory infection duration, modulation of gut-brain axis markers, and improvement of bowel function and inflammatory markers in older adults.
B. longum is positioned as a premium Bifidobacterium in capsule and sachet products and is increasingly the strain of choice in gut-brain and immune-positioned dietary supplement formulations.
Where it is used
- Adult capsules, tablets, and sachets for gut microbiome support
- Functional yogurt and fermented dairy
- Immune and seasonal wellness supplements
- Stress and mood-support formulations (gut-brain axis)
- Senior nutrition and gut barrier products
- Infant formula fortification (subsp. infantis)
- Pediatric probiotic drops and sachets
- Synbiotic formulations with prebiotic fibers
- Postbiotic and tyndallized cell applications
Technical data
| Item | Specification |
|---|---|
| Appearance | Off-white to pale beige free-flowing powder |
| Viable cell count | ≥ 200 billion CFU/g (100B, 200B, 500B grades) |
| Strain identity | Confirmed by 16S rRNA sequencing and species-specific PCR |
| Moisture (loss on drying) | ≤ 4.0% |
| Particle size | ≥ 95% through 80 mesh |
| Heavy metals (as Pb) | ≤ 1 mg/kg |
| Arsenic | ≤ 0.5 mg/kg |
| Salmonella | Absent in 25 g |
| E. coli | Absent in 10 g |
| Staphylococcus aureus | Absent in 10 g |
| Yeast and mold | ≤ 50 CFU/g |
| Shelf life | 24 months from manufacture under recommended storage |
| Storage | −18 °C sealed; 2 to 8 °C after opening |
Ready to discuss business?
Send us your spec and requirement. We will respond with availability and pricing within 24 hours.